Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...

Insights from Steven Cohen (Trades, Portfolio)'s First Quarter 2025 13F Filing. Warning! GuruFocus has detected 4 Warning ...

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Danaher (NYSE:DHR) stock falls even as the company beats Q2 2025 forecasts despite an underperformance at its Life Sciences ...

This was the stock's third consecutive day of losses.

The industrial and medical device maker posted revenue of $5.94 billion in the period, which also topped Street forecasts. Eight analysts surveyed by Zacks expected $5.84 billion. Danaher expects full ...

The Danaher Business System focuses on continuous improvement, including the acceleration of core growth and margin expansion through marketing initiatives and innovation, which appears positive for ...

Danaher India partners with THSTI to enhance biomanufacturing, life sciences, and healthcare solutions in India, focusing on ...

Danaher India partners with THSTI to build India’s biomanufacturing capacity, drive healthcare innovation, and support ...